Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including complex robotic surgery, clinical trials and novel therapeutics such as precision medicine, CAR T-Cell Therapy and other forms of immunotherapy.
Identifying a Novel Gene Associated with Prognosis in Ovarian Cancer
Investigators at Rutgers Cancer Institute of New Jersey have determined that an overabundance of a novel gene known as ADNP in an aggressive form of ovarian cancer may serve as a predictive tool. Rutgers Cancer Institute researcher Michael L. Gatza, PhD, assistant professor of radiation oncology at Rutgers Robert Wood Johnson Medical School, is the senior and corresponding author of the work published in the November 22 online edition of EBioMedicine. Learn more
Proton Therapy Well Tolerated in Patients Undergoing Breast Conserving Surgery
As members of the only hospital-based proton therapy program in New Jersey, investigators at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, conducted a retrospective review of patients treated with proton therapy following breast-conserving surgery and found acceptable toxicity rates. Results were presented at the San Antonio Breast Cancer Symposium last month by Nisha Ohri, MD, radiation oncologist at Rutgers Cancer Institute and assistant professor of radiation oncology at Rutgers Robert Wood Johnson Medical School. Learn more
$250K Grant Supports Exploration of Lung Cancer Tumor Microenvironment
Fueling investigation by those who collaborate under a National Cancer Institute-recognized research consortium partnership between Rutgers Cancer Institute of New Jersey and Princeton University, the GO2 Foundation for Lung Cancer awarded $250,000 for research on treatment resistance in non-small cell lung cancer. The grant will support Rutgers Cancer Institute researchers ‘Jessie’ Yanxiang Guo, PhD, assistant professor of medicine at Rutgers Robert Wood Johnson Medical School; and Shawn Davidson, PhD, Lewis-Sigler Institute Fellow in the Molecular Biology Department at Princeton University.Learn more
Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma
In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma, Rutgers Cancer Institute of New Jersey investigators examined characteristics, treatment patterns, and disease outcomes, and determined accurate diagnosis of the disease requires ongoing analysis. Results were shared at the American Society of Hematology Annual Meeting in Orlando last month by Kevin David, MD, hematologist/oncologist at Rutgers Cancer Institute and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School.
Close to 200 attendees gathered last month at the Future of Women’s Cancer Care is Here symposium hosted by Rutgers Cancer Institute of New Jersey and the Rutgers University Alumni Association. Expert panelists from Rutgers Cancer Institute shared why they went into the field of cancer research and care, as well as provided an update on the advances in cancer treatment. Panelists included Drs. Janice Mehnert, Eileen White, Deborah Toppmeyer, Shicha Kumar and Ruth Stephenson, all faculty at Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School. Learn more
